The Potential of Human Mesenchymal Stem Cells

For this article, Eugene Russo interviewed Mark F. Pittenger, director of discovery research at Osiris Therapeutics. Data from the Web of Science (ISI, Philadelphia) show that Hot Papers are cited 50 to 100 times more often than the average paper of the same type and age. M.F. Pittenger, A.M. Mackay, S.C. Beck, R.K. Jaiswal, R. Douglas, J.D. Mosca, M.A. Moorman, D.W. Simonetti, S. Craig, D.R. Marshak, "Multilineage potential of adult human mesenchymal stem cells," Science, 284:143-7, April 2,

Written byEugene Russo
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

It was careful cell characterization, careful in vitro assays, and careful clonal analysis that contributed to the paper's impact, suggests Pittenger, who is now Osiris' director of discovery research. These elements together, he says, demonstrated that human mesenchymal stem cells (hMSCs) could be derived from bone marrow cells. Osiris investigators achieved differentiation into adipocytes (fat cells), chondrocytes (cartilage cells), and osteocytes (bone cells).

Initially, his group sought to generate in vitro assays that would be helpful in understanding cellular differentiation. "We went through a lot of literature, we tried a lot of different methods for differentiating the cells," he explains. "Some worked, some didn't." Then, through trial and error, they found the right combination of hormones, growth factors, vitamins, and serum and the correct methods to get the hMSCs to differentiate into each lineage. For example, to achieve adipocytic differentiation, the cells had to be confluent; whereas, too high a ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies